Study Summary
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Want to learn more about this trial?
Request More InfoInterventions
Cyclophosphamide injectionDRUG
500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
Fludarabine InjectionDRUG
30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
CD19-CD34t metabolically programmed CAR transduced T-cellsBIOLOGICAL
Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hollings Cancer Center at Medical University of South Carolina | Charleston | South Carolina | United States |